No Prescription |
 |
 | ||
|
Elidel Cream Generic Pimecrolimus Cream |
|
| ||
No Prescription » Prescription Drugs 6 » Elidel Cream Generic Pimecrolimus Cream Medical Information: Elidel is a non-steroidal cream that relieves mild to moderate symptoms of eczema a skin condition marked by itchy red patches that often crust scale and ooze. Elidel is approved for use in adults and children over 2 years old; it can be used for short-term treatment or on-and-off treatment over longer periods of time. Elidel is considered an effective alternative for people who cannot tolerate or do not respond to conventional eczema therapies. Treating atopic dermatitis also known as eczema in patients who cannot take or whose symptoms do not respond to other treatments. Elidel is a topical immunomodulator which means it modulates or "changes" the body's immune system in some way. In eczema it works by preventing the activation of certain immune cells and blocks the release of certain chemicals that cause inflammation redness and itching of the skin. Elidel « (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable. Buy Elidel Cream Generic Pimecrolimus Cream and other Prescription Drugs 6 products online at Medstore. 3665
About Elidel Cream Generic Pimecrolimus Cream: Product Type: Prescription Drugs 6 Elidel Cream ( Generic Pimecrolimus Cream ) Elidel Cream (Generic Pimecrolimus Cream) Generic Pimecrolimus Cream 1% 2 x 15gm Tube Generic Pimecrolimus Cream Elidel Cream
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
